Search

Displaying results 7891 - 7900 of 10000 in total
  1. Drug

    XL820

    go.drugbank.com/drugs/DB05146
    Investigational

    XL820 is a solid. … variety of human cancers.

  2. Drug

    BBV152

    go.drugbank.com/drugs/DB15847
    Investigational

    or a novel TLR7/8 agonist adsorbed gel. … BBV152 is a vaccine candidate created by the Indian Council of Medical Research (ICMR).

  3. Drug

    N-Formylmethionine

    go.drugbank.com/drugs/DB04464
    Experimental

    This process occurs in Escherichia coli and other bacteria as well as in the mitochondria of eucaryotic cells. … N-Formylmethionine is effective in the initiation of protein synthesis. The initiating methionine residue enters the ribosome as N-formylmethionyl tRNA.

  4. Drug

    Briakinumab

    go.drugbank.com/drugs/DB05459
    Investigational

    Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. … As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.

  5. Drug

    PRX-07034

    go.drugbank.com/drugs/DB05993
    Experimental

  6. Drug

    Contusugene ladenovec

    go.drugbank.com/drugs/DB05322
    Investigational

    Advexin is a well-tolerated and efficacious treatment for numerous cancers, both as monotherapy and in combination with radiation and/or chemotherapy agents. … INGN 201(Advexin) is a replication-impaired adenoviral vector that carries the p53 gene, has been evaluated in both preclinical and clinical trials.

  7. Drug

    TL-895

    go.drugbank.com/drugs/DB16471
    Investigational

    TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively.

  8. Drug

    Prenalterol

    go.drugbank.com/drugs/DB13777
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    XEN-D0101

    go.drugbank.com/drugs/DB06020
    Experimental

    XEN-D0101 is an investigational drug developed by Xention Inc. for the treatment of Atrial Fibrillation. XEN-D0101 works by being a selective antagonist of the voltage-gated potassium channel Kv1.5.

  10. Drug

    CMC 001

    go.drugbank.com/drugs/DB05353
    Investigational

    CMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract.